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Abstract
The expression of the angiogenic phenotype is regulated by a balance of pro-angiogenic and anti-angiogenic factors
released into the tumor microenvironment. Nuclear protein 7 (NOL7), a novel tumor suppressor, acts as a master
regulator of angiogenesis by downregulating pro-angiogenic factors and upregulating anti-angiogenic factors. Using
cervical cancer as a model of investigation, we have previously shown that loss of NOL7 mRNA and protein expres-
sion is observed as early as the premalignant phase. Analysis of the gene failed to identify tumor-specific promoter
methylation or coding region mutations, suggesting that NOL7 loss may be mediated by aberrant expression of its
upstream regulators. In this study, we show that the RB tumor suppressor gene (RB) positively regulates NOL7 at the
transcriptional level by recruiting transcription factors and transcription machinery proteins to its promoter region.
Conversely, the loss of RB represses NOL7 transcription by inhibiting assembly of these proteins. This loss of
NOL7 expression is also observed in RB-deficient human malignancies. Together, this work further characterizes
the transcriptional activator function of RB and defines a potential role for RB in regulating angiogenesis through
activation of NOL7. Current anti-angiogenic therapies lack long-term efficacy, as they are unable to target the diverse
angiogenic signals generated by tumors. Our data provide evidence to support the hypothesis that reactivation of pRB
can potentially modulate the expression of the angiogenic phenotype through regulation of NOL7. Therefore, this
knowledge may be employed to design more comprehensive and effective therapies.
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Introduction
Angiogenesis is a hallmark of cancer and is considered an essential
step for tumor growth and metastasis [1,2]. The expression of the
angiogenic phenotype is regulated by a balance of pro-angiogenic
and anti-angiogenic factors released in the tumor microenvironment
[1]. Anti-angiogenic therapies often lack long-term efficacy because
they are generally designed to target specific pathways or molecules,
and blocking one such step may activate alternative mechanisms or
promote resistance through alternative mechanisms [3–5]. To better
understand the complex interplay between angiogenesis regulation
and other important processes in the pathogenesis of cancer, it is
therefore important to characterize novel angiogenesis regulators
and their control by key tumor suppressor pathways.
Using cervical cancer (CC) as model of investigation, we have
previously identified a novel tumor suppressor gene, NOL7 [6].
Nuclear protein 7 (NOL7) inhibits angiogenesis by downregulating
pro-angiogenic factors, including vascular endothelial growth factor,
and upregulating anti-angiogenic factors, such as thrombospondin-1
[6,7]. This ability to differentially modulate angiogenesis-related pro-
teins suggests that NOL7 may function as a master regulator of angio-
genesis [7]. NOL7 expression is significantly reduced in CC cell lines
and tumors [6,8], and recent reports have demonstrated that reduced
NOL7 expression is significantly associated with higher relapse risk in
CC [9]. However, the mechanisms explaining NOL7 loss of expression
are not known.
Abbreviations: CC, cervical cancer; NOL7, nuclear protein 7; VEGF, vascular endo-
thelial growth factor; TSP-1, thrombospondin-1
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Previously, we evaluated NOL7 expression in normal, premalignant,
and CC tissues and determined that the initial loss of protein expres-
sion was observed at the early premalignant phases [8]. While NOL7
allelic loss and genomic alterations have been reported, these changes
are typically not observed until after the development of malignant
disease, suggesting that alternative mechanisms are responsible for the
loss of NOL7 expression at the premalignant stage [10,11]. We identi-
fied the NOL7 promoter region and assessed its methylation and muta-
tion status [8,12]. This analysis failed to identify any directly deleterious
methylation or mutation patterns specific in either CC tissue or cell lines
[8,12]. In addition, analysis of the NOL7 3′untranslated region (UTR)
failed to identify conserved cis-elements or microRNA binding sites,
suggesting that loss of NOL7 expression does not occur by way of
post-transcriptional or translational mechanisms. These data suggest that
down-regulation of NOL7 at the premalignant phases of CC results
from aberrant expression of its upstream regulators.
CC development is driven in part by the HPV oncoproteins E6 and
E7 that contribute to malignant transformation by inducing genomic
instability, inactivating the p53 and RB tumor suppressors, and pro-
moting angiogenesis [13,14]. In CC, the RB, p107, and p130 pocket
proteins are inactivated by the HPV E7 gene product that both tar-
gets the pocket proteins for degradation and inhibits their interactions
with E2Fs [15,16]. Previous studies have detected a significant loss of
RB protein (pRB) expression between the premalignant cervical intra-
epithelial neoplasia II and III phases [17]. Interestingly, our analysis of
premalignant cervical tissue depicted a similar loss of NOL7 expression
at the same interval [8]. Analysis of pRB expression in CC cell lines
demonstrated a strong correlation between pRB and NOL7 expression
levels in 81% of cell lines (data not shown) [8]. In addition, reactiva-
tion of RB in CC cell lines results in the induction of NOL7 transcript
levels [18]. This suggested that pRB positively regulates NOL7 expres-
sion and that RB loss and reduced NOL7 expression observed in CC
are mechanistically linked. Although known primarily as a transcrip-
tional repressor, recent data have suggested that pRB can activate
gene transcription by interacting with site-specific transcription factors
(TFs) such as E2F1 and SP1 [19,20]. The NOL7 promoter region
has predicted binding sites for these TFs, and we have previously
demonstrated that SP1 associates with the NOL7 promoter [12].
The objective of this study was to determine if pRB regulates NOL7
transcription and characterize the mechanism behind this regulation.
In this report, we describe a novel role for the RB tumor suppressor
in transcriptionally activating the anti-angiogenic protein, NOL7. We
demonstrate that pRB stimulates NOL7 transcription by interacting
with and recruiting TFs, coactivators, and chromatin remodeling en-
zymes to the NOL7 promoter region. We also show that RB loss sig-
nificantly downregulates NOL7 promoter activity and protein levels.
This correlation between RB inactivation and decreased NOL7 expres-
sion is also observed in different types of human malignancies. This
suggests that RB-mediated NOL7 regulation is not restricted to a single
cell type and that RB loss results in subsequent NOL7 down-regulation
during malignant transformation. Taken together, our data identify a




HeLa andHec-1A (ATCC,Manassas, VA) were cultured as described
previously [8]. GP2-293 (Clontech, Mountain View, CA) and HaCaT
(ATCC) cells were cultured in Dulbecco’s modified Eagle’s medium
(Invitrogen, Carlsbad, CA). HPV E7 expression was induced by treat-
ing cells with 1 μM 4-hydroxytamoxifen (Sigma, St. Louis, MO)
containing media for 20 hours. For generation of stable cell lines,
media were supplemented with puromycin (1 μg/ml; Sigma) or geneticin
(300 μg/ml; Invitrogen).
Polymerase Chain Reaction Amplification, Plasmids,
and Cloning
Polymerase chain reaction (PCR) was carried out using Phusion
High-Fidelity Master Mix (New England Biolabs, Ipswich, MA)
[12]. The full-length NOL7 promoter (FL) was subcloned into the
pGL4.20 vector (Promega, Madison, WI) [12]. The promoter sub-
regions R1, R2, R3, ΔR1, and ΔR3 were PCR amplified using primers
(Table W1) and cloned into the pGL3-basic vector (Promega). Bio-
tinylated fragments of the NOL7 promoter, subregions, p21 promoter,
and a random nongenic region (R02; Switchgear Genomics, Menlo
Park, CA) were obtained by PCR amplification using biotin-labeled
primers (Table W2). The pCMV-VSV-G, E7, and E1A (wild-type
and LXCXE mutant) vectors were obtained from the following labora-
tories: DiMaio, Munger, Schlegel, and Weinberg [18,21–23]. The
pIRES-GFP and pBabe-puro-ER-E7 plasmids were generously provided
by Dr Kay Macleod. The wild-type and mutant E7 and E1A genes were
subcloned into the pIRES-green fluorescent protein (GFP) vector.
Transfections
Transfections were performed using X-fect (Clontech) as per the
manufacturer’s guidelines. For stable RB knockdown, cells were trans-
fected with pGFP-V-RS plasmid (Origene Technologies, Rockville,
MD) containing either scrambled or RB shRNA (5′-AGCAGTTC-
GATATCTACTGAAA-3′) followed by selection with puromycin.
HaCaT and Hec-1A cell lines stably expressing the NOL7 promoter–
luciferase were obtained by transfecting cells with pGL4.20-NOL7
promoter plasmid followed by selection with puromycin. These
HaCaT-luc or Hec-1A–luc cells were transiently transfected with
pIRES-GFP vector containing either wild-type or LXCXE mutant E7
or E1A genes. HaCaT cells were transiently transfected with FL, R1,
R2, R3, ΔR1, or ΔR3 vectors along with pIRES-GFP.
Retrovirus Production and Transduction
GP2-293 cells were co-transfected with pBabe-puro-ER-E7 and pCMV-
VSV-G plasmids. Forty-eight hours after transfection, the culture medium
containing the retrovirus particles was harvested, concentrated using the
Retro-X Concentrator (Clontech), and reconstituted in media containing
polybrene (8 μg/ml; Millipore, Billerica, MA). Cells were incubated in
this media for 8 hours followed by a media change. This infection was
repeated one more time, followed by selection in media containing puro-
mycin to obtain cells stably expressing a tamoxifen-inducible HPV E7.
Luciferase and GFP Assays
Luciferase assays were performed as described previously [12]. GFP
expression was measured using the Synergy HT reader (BioTek,
Winooski, VT). The GFP values were used to normalize the luciferase
activity. Experiments were performed in triplicates.
Chromatin Immunoprecipitation and Reverse
Chromatin Immunoprecipitation
Chromatin Immunoprecipitation (ChIP) assays were performed for
the TFs pRB, E2F1 to E2F4, or SP1 using NOL7 promoter–specific
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primers as described previously [12]. One microgram of pRB, phospho-
RB (Ser 780-790-807-811; Cell Signaling Technology, Danvers, MA),
E2F1 to E2F4 (Santa Cruz Biotechnology, Santa Cruz, CA), SP1, and
mouse or rabbit IgG (Millipore) antibodies were used. For the reverse
ChIP (ReChIP) experiments, the pRB-bound chromatin-protein com-
plexes were precipitated by incubation with 1 μg of E2F3, BRG-1,
BRM, p300 (Santa Cruz Biotechnology), PCAF (Cell Signaling Tech-
nology), SP1, RNA Polymerase II (RNA Pol II), and mouse IgG or
rabbit IgG (Millipore) antibodies, followed by elution and PCR analysis
as described previously [12]. Each ChIP or ReChIP experiment was
repeated twice. ChIP-grade antibodies were used for these assays, which
have also been previously validated in other studies [12,20,24–27].
Western Blot Analysis
Western blot analysis was performed as described previously [12].
The following primary antibodies were used: β-actin (Abcam, Cam-
bridge, MA), E2F4 (Bethyl Laboratories, Montgomery, TX), pRB,
BRM, PCAF (Cell Signaling Technology), E2F1, RNA Pol II, SP1
(Millipore), E2F2, BRG-1, p300 (Santa Cruz Biotechnology), E2F3,
NOL7, p107, and p130 (Sigma). The blots were incubated with
the appropriate secondary antibodies, developed as described before
[12]. The Quantity One software (Bio-Rad, Hercules, CA) was used
to quantify individual protein bands from densitometrically scanned
Western images.
Streptavidin Pull-down Assay
Streptavidin pull-down assay (SAPA) was performed as described
previously with few modifications [19,28,29]. HaCaT cell nuclear
extracts were prepared using the Nuclear Extract Kit (Active Motif,
Carlsbad, CA). Each biotinylated DNA fragment was incubated with
100 μg of HaCaT nuclear extract by rotation at 4°C, overnight. Protein-
DNA complexes were precipitated using streptavidin Dynabeads
(Invitrogen). Beads were washed thoroughly and boiled in sodium
dodecyl sulfate sample buffer to elute the bound proteins, which were
then analyzed by Western blot analysis.
Tissue Microarray and Immunohistochemistry
Immunohistochemistry was performed with the approval of the
University of Chicago Institutional Review Board. Normal retina and
retinoblastoma tissue microarrays were obtained from US Biomax Inc
(Rockville, MD). Normal lung, cervix, oral mucosa, cervical, HPV-
positive oropharyngeal, and small cell lung cancer (SCLC) tissue micro-
arrays were generated using a Beecher Instruments ATA-27 Automated
Tissue Arrayer. Deparaffinized sections were microwaved in ET buffer,
NOL7 (1:120; Sigma) and RB (1:100; Cell Signaling Technology)
primary antibodies were applied for 1 hour at room temperature, and
the rabbit or mouse EnVision+ Kit (DAKO, Carpinteria, CA) was
used for detection. All sections were counterstained with hematoxylin
and scored on a 0 to 3 scale, with 0 being the lowest staining and 3
the greatest.
Statistical Analysis
The error bar values are reported as mean ± SEM. A two-tailed
Student’s t test was used to compute P values, and the graphs were
made using SigmaPlot software version 10 (Systat, Chicago, IL).
Results
pRB Repression Causes Down-regulation of NOL7 Expression
NOL7 expression is significantly downregulated in CC where RB
is functionally inactivated by the HPV E7 oncoprotein [8,30]. To
examine the effect of RB knockdown on NOL7 expression, we stably
transfected HaCaT cells with either control or RB-specific shRNA.
These cells have a nonfunctional p53 and therefore resistant to p53-
dependent cell death on RB loss, thereby simulating CC that has both
Rb and p53 inactivated [31,32]. Western blot analysis demonstrated
that RB knockdown in HaCaT cells resulted in significantly reduced
levels of NOL7 protein (Figure 1A), suggesting that pRB positively
regulates NOL7 expression. To determine if pRB is a direct upstream
modulator of NOL7 expression, we generated cells stably expressing
a tamoxifen-inducible HPV E7 construct. This analysis helped us
assess NOL7 protein expression after conditional and transient RB
Figure 1. pRB repression downregulates NOL7 protein expression. (A) Representative Western image illustrating endogenous pRB and
NOL7 expression in pRB knocked down HaCaT cells. (B) HaCaT–HPV E7 cells were treated with media containing 1 μM tamoxifen for
20 hours. Representative Western image depicting expression of endogenous pRB and NOL7 +/− treatment with tamoxifen and quanti-
fication of endogenous pRB and NOL7 protein levels.
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loss. As Figure 1B demonstrates, tamoxifen treatment decreased
endogenous pRB expression by 50%. Furthermore, cells with reduced
pRB levels also exhibited reduced endogenous NOL7 protein expres-
sion (Figure 1B). Taken together, these data suggest that pRB is a
positive upstream modulator of NOL7 expression.
pRB Positively Regulates NOL7 at the Transcriptional Level
As pRB loss negatively affected NOL7 protein expression, we
sought to determine the effect of RB loss on NOL7 transcription.
We generated NOL7 promoter–luciferase construct expressing cell
lines, which were then transiently transfected with either wild-type
HPV E7 or E1A or their respective mutant forms that are unable
to bind to and degrade pRB (Figure 2A) [33]. In addition to HaCaT
cells, we used Hec-1A cells, which express a variant p53 protein that
is less efficient in inducing cell death [34,35]. Endogenous pRB levels
were reduced exclusively in wild-type E7- and E1A-transfected cells
(Figure 2B). NOL7 promoter activity was significantly reduced (P <
2 × 10−4) in Hec-1A–luc and HaCaT-luc cells where pRB expression
was downregulated (Figure 2C ). These data demonstrate that pRB
positively regulates NOL7 transcription.
pRB-interacting Proteins E2F3 and SP1 Are Enriched
on the NOL7 Promoter
pRB lacks a DNA-binding domain and therefore is localized to
gene promoters through interaction with site-specific TFs including
the E2F family proteins [36,37]. Recent reports have shown that
pRB positively regulates gene transcription by interacting with SP1
and E2F1 [19,20]. In silico analysis using promoter prediction pro-
grams identified seven SP1 and two E2F binding sites within the
NOL7 promoter (Figure 3A) [38,39]. Using ChIP analysis, we deter-
mined that SP1 associated with the NOL7 promoter in all cell lines
tested (Figure 3B), while E2F1 and E2F2 showed greater association
with the NOL7 promoter in HeLa cells (Figure 3C ). In contrast,
E2F3 and E2F4, which also interact with pRB, associated with the
NOL7 promoter to a greater extent in HaCaT and Hec-1A cells
compared to HeLa cells (Figure 3C) [37]. Together, these data demon-
strated that pRB-interacting TFs associated with the NOL7 promoter,
thereby suggesting that pRB may localize to the NOL7 promoter
through interaction with these TFs.
Hypophosphorylated pRB Stimulates NOL7 Transcription
by Associating with Its Promoter
Because pRB-interacting TFs associated with the NOL7 promoter
(Figure 3, B and C ), a ChIP assay was performed to determine if
pRB positively regulated NOL7 transcription by associating with its
promoter. This analysis demonstrated that pRB specifically associated
with the NOL7 promoter in HaCaT and Hec-1A cells but not in HeLa
cells, which have reduced pRB expression because of inhibition by
HPV E7 (Figure 3, D–F ). This suggested that pRB may induce
NOL7 transcription by interacting with TFs, E2Fs, or SP1 that were
also enriched on its promoter (Figure 3, B and C ).
pRB is hyperphosphorylated and inactive following the G1-S transi-
tion of mammalian cell cycle [40]. Therefore, we assessed the enrich-
ment of hyperphosphorylated RB (ppRB) on the NOL7 promoter by
repeating the ChIP analysis using antibodies that recognize key phos-
phorylation sites (Ser 780-795-807-811) on pRB [41–45]. As shown in
Figure 3E , ppRB did not associate with the NOL7 promoter, sug-
gesting that only hypophosphorylated pRB interacts with the NOL7
promoter. Next, we evaluated the effect of cell cycle phase–specific
changes in hypophosphorylated pRB for effects on NOL7 expression.
We treated cells with aphidicolin and nocodazole to arrest them at
S phase or M phase of cell cycle, respectively (Figure W1A). NOL7
protein expression was downregulated in G2 and early M phases, which
have increased ppRB levels, compared to G1 and early S phases
(Figure W1B). These data suggest that hypophosphorylated pRB
drives NOL7 transcription by associating with its promoter and cell
cycle phase–specific pRB phosphorylation downregulates NOL7
expression by limiting hypophosphorylated pRB availability.
Figure 2. pRB positively regulates NOL7 transcription. (A) Sche-
matic illustrating generation of stable cell lines expressing the NOL7
promoter–luciferase, transfected with either wild-type or mutant (*)
forms of HPV E7 or E1A proteins. (B) Western blot analysis to evalu-
ate endogenous pRB expression in these cells. (C) Relative NOL7
promoter–luciferase activity represented as a percentage of the
wild-type E7 or E1A transfectants. The figure represents triplicate
experiments with error bars corresponding to SEM.
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To evaluate the enrichment of pRB and pRB-interacting proteins
on the NOL7 promoter through an alternate approach, SAPA analy-
sis was performed. This is a semiquantitative assay that is extremely
useful in analyzing multiple TFs that bind to a promoter from a
non–cross-linked nuclear extract [28,29]. SAPA analysis was performed
using a biotinylated NOL7 promoter fragment that was incubated with
non–cross-linked nuclear extract, followed by precipitation of the
promoter-bound protein complexes with streptavidin beads and analy-
sis of the bound proteins. A biotinylated p21 promoter was used as a
positive control for this assay, as p21 is positively regulated by pRB and
SP1 [19], and a random nongenic region (R02) was used as a negative
control. SAPA analysis demonstrates enrichment of pRB, SP1, and
E2F3 on the NOL7 promoter (Figure W2). In addition, RNA Pol II
was enriched on the NOL7 promoter region (Figure W2), suggesting
that pRB activates NOL7 transcription by interacting with its promoter
along with the proteins E2F3, SP1, and RNA Pol II.
pRB Interacts with TFs, RNA Pol II, Transcriptional
Coactivators, and Chromatin Remodeling Enzymes at
the NOL7 Promoter
pRB associates with DNA through interactions with TFs and chro-
matin remodeling proteins [20,25]. Therefore, we hypothesized that
pRB is part of a protein complex that assembles on NOL7 promoter.
To assess this possibility, we performed a ChIP-ReChIP assay (Fig-
ure 4A). Strong interaction between SP1, RNA Pol II, and pRB was
observed in the HaCaT and Hec-1A cell lines, whereas E2F3 interac-
tion with pRB was more pronounced in the HaCaT cells (Figure 4B).
In addition, the SWI/SNF component BRM and coactivators p300
Figure 3. pRB and pRB-interacting TFs associate with the NOL7 promoter. (A) NOL7 promoter schematic depicting predicted SP1 and
E2F binding sites. (B–E) ChIP analysis to evaluate SP1, E2F, pRB, and ppRB association on the NOL7 promoter in HeLa, HaCaT, and
Hec-1A cell lines as described previously. (F) Western blot analysis depicting expression of TFs in these cell lines.
Figure 4. pRB interacts with TFs, RNA Pol II, coactivators, and chro-
matin remodeling proteins at the NOL7 promoter. (A) Schematic
depicting the steps in the ReChIP assays. (B) Representative ReChIP
PCR image for HaCaT and Hec-1A cells. Each ReChIP experiment
was repeated twice.
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and PCAF interacted with pRB at the NOL7 promoter in both cell
lines, while the pRB-BRG-1 interaction was more specific to HaCaT
cells (Figure 3B). These data indicate that pRB interacts with TFs,
RNA Pol II, coactivators, and chromatin remodeling proteins, thereby
suggesting that it is part of a transcriptional complex that is enriched
on the NOL7 promoter
pRB Recruits SP1, Transcriptional Coactivators, and
Chromatin Remodeling Proteins to the NOL7 Promoter
Our analysis indicated that pRB was part of a complex of proteins
that bound the NOL7 promoter. To functionally characterize pRB’s
role in the assembly of this complex, we evaluated the effect of RB
loss on the enrichment of these proteins on the NOL7 promoter by
performing SAPAs in cells where RB expression was knocked down.
We observed that knockdown of RB significantly lowered pRB en-
richment on the NOL7 promoter (Figure 5A). Interestingly, RB loss
also reduced SP1, BRG-1, BRM, p300, and PCAF binding to the
NOL7 promoter, suggesting that pRB was essential for recruitment
of these proteins to the NOL7 promoter (Figure 5A). These data sug-
gested that pRB recruits multiple proteins, including components of
the basal transcriptional machinery to drive NOL7 transcription.
NOL7 Repression Is Not Mediated by Binding of an
Alternative pRB-E2F Complex to Its Promoter
In addition to binding to pRB, E2F family members can also com-
plex with the other pocket protein family members, p107 and p130,
to repress gene transcription [37]. In particular, “pocket protein shuf-
fling” occurs when pRB is knocked down or out, such that new com-
plexes between the “activator” class of E2Fs (E2F1, E2F2, and E2F3)
and p107 or p130 are formed [46]. We assessed whether an alternative
repressor complex downregulated NOL7 transcription in the absence
of pRB. Overall, no significant change in binding of the pocket pro-
teins, p107 and p130, and various E2Fs was observed on pRB loss
(Figure 5B). p107, E2F1, E2F2, and E2F4 continued to demonstrate
very weak or no enrichment on the NOL7 promoter, suggesting that
pRB loss does not result in the recruitment of an alternative pocket
protein–E2F complex to the NOL7 promoter.
The NOL7 Promoter Contains Multiple Binding Sites for
pRB-TF Complexes
Next, we sought to further define the functional pRB-TF complex
binding region within the NOL7 promoter. For this purpose, the
NOL7 promoter was divided into three nonoverlapping subregions
(R1–R3; Figure 5A). SAPA analysis with nonoverlapping NOL7
promoter subregions demonstrated comparable pRB, E2F3, and
SP1 enrichment on each subregion (Figure 6A), suggesting that
the NOL7 promoter contains multiple binding sites for pRB-TF
complexes. To assess the functional contribution of each of these
subregions to NOL7 transcriptional activation, we cloned promoter
subregions into luciferase reporter constructs and compared the
activity of each subregion to the FL. R3 exhibited the greatest lucif-
erase reporter gene expression compared to the other subregions (Fig-
ure 6B). However, it had 45% lower promoter activity compared to
Figure 6. pRB-TF complexes havemultiple binding sites in the NOL7
promoter. (A) NOL7 promoter schematic depicting predicted E2F,
SP1 binding sites, and NOL7 promoter subregions R1 to R3. SAPA
analysis of the proteins coprecipitatedwith eachpromoter subregion
by Western blot analysis. (B) Relative luciferase activity of the NOL7
promoter subregions R1 to R3, ΔR1 (R2 + R3), orΔR3 (R1+ R2) rep-
resented as a fraction of the FL transfectants. The figure represents
triplicate experiments with error bars corresponding to SEM.
Figure 5. pRB activates NOL7 transcription by recruiting SP1, co-
activators, and chromatin remodeling proteins to its promoter. (A
and B) SAPA analysis was performed on cells expressing control
(SCR) or RB-specific shRNA to assess the enrichment of proteins on
the NOL7 promoter on RB loss. Each SAPA experiment was repeated
twice. A representative Western image depicting NOL7 promoter–
enriched proteins in control or pRB knockdown cells is shown here.
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the FL (P = 8 × 10−5; Figure 6B), suggesting that while R3 contained
necessary elements for basal promoter activity, optimum transcrip-
tional activation of NOL7 required the interaction of the pRB-TF
complexes at all three regions.
NOL7 Protein Expression Is Decreased in
Human Malignancies Lacking pRB
The RB pathway is disrupted in a number of human cancers
through several different mechanisms including RB gene deletions
(observed in retinoblastoma and SCLC) and RB protein degradation
[observed in CC and HPV-associated oropharyngeal cancer (HPV +
OPC)] [15]. To determine whether RB protein loss correlated with
downregulated NOL7 levels in human tumors, we evaluated NOL7
and RB protein levels in human retinoblastoma, CC, SCLC, and
HPV + OPC tissues. Previous studies have observed significantly lower
pRB expression in these tumors [47–50]. As expected, robust pRB
and NOL7 expression was observed in 100% of normal lung, retinal,
cervical, and oral mucosa tissues (Figure 7, A–D, upper panels). By
contrast, retinoblastoma, CC, and HPV + OPC tissues expressed sig-
nificantly lower levels of pRB (Figure 7, A, C , and D, lower panels);
these results were in accordance with previous studies. Strikingly, these
tumors had reduced NOL7 levels, which strongly correlated with pRB
expression. While prior reports have detected low or absent pRB ex-
pression in 100% of SCLC tissue samples [49], we observed that 76%
of the SCLC samples exhibited low pRB expression. However, again
the NOL7 expression closely correlated with pRB levels as observed in
the other RB null tumors (Figure 7). These data showed that NOL7
was significantly downregulated in tumors that lack pRB, irrespective
of the mechanism of RB inactivation.
Discussion
Angiogenesis is a critical step in tumor progression and metastasis
[1,2]. The diversity and redundancy of angiogenic pathways has ham-
pered the design of effective and long-term anti-angiogenic therapies
[4,51]. We identified a novel anti-angiogenic protein, NOL7, that
may function as master regulator of angiogenesis by downregulating
pro-angiogenic and upregulating anti-angiogenic factors [6,7]. NOL7
expression is lost in CC where HPV E7 inactivates the RB tumor sup-
pressor protein [8,30]. Here, we demonstrate that the RB tumor sup-
pressor positively regulates NOL7 transcription. Using multiple
approaches, we show that pRB positively regulates NOL7 transcription
by recruiting TFs, chromatin remodeling enzymes, and coactivator pro-
teins to form a transcriptional activation complex at the NOL7 pro-
moter. RB loss prevents formation of this complex, thereby resulting
in down-regulation of NOL7 transcription and expression. This
down-regulation of NOL7 expression is also observed in RB-deficient
human tumors irrespective of the mechanism of RB inactivation.
Traditionally, pRB is considered to be a repressor of E2F target gene
transcription [37,52]. Recent reports have demonstrated that pRB can
also synergize with site-specific TFs to activate transcription [19,20].
We have demonstrated that pRB positively regulates NOL7 transcrip-
tion by recruiting transcriptional coactivators and remodeling proteins
to its promoter (Figure 8). These findings are in agreement with our
preliminary data showing increased acetylated histone H4 enrichment
Figure 7. NOL7 expression is downregulated in human malignancies that lack pRB. Immunohistochemistry analysis demonstrating pRB
and NOL7 expression levels in (A) normal retina and retinoblastoma, (B) normal lung and SCLC, (C) normal cervix and CC, and (D) normal
oral mucosa and HPV + OPC tissues. Data are represented as percentage of tumor specimens demonstrating a staining intensity ranging
from 0 to 3+.
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at the NOL7 promoter (data not shown). Future studies will focus
on determining the changes in chromatin conformation and histone
modification at the NOL7 promoter on pRB loss. We determined that
the NOL7 promoter has multiple pRB-TF complex binding sites,
which collectively contribute to NOL7 transcriptional activation (Fig-
ure 6). The p300 coactivator protein is known to facilitate enhancer
activity for several genes [53–55]. We have shown that pRB recruits
p300 to the NOL7 promoter; therefore, it may be important to char-
acterize each of the pRB-TF binding sites to determine if they possess
enhancer activity.
pRB regulates diverse cellular processes such as differentiation, apop-
tosis, growth arrest, cell cycle, and metabolism in a context-specific
manner. However, a role for pRB in inhibiting angiogenesis has not
been clearly established [15]. Studies have implicated phosphorylated
forms of the pRB family proteins in promoting angiogenesis, suggest-
ing that hypophosphorylated and active pRB may inhibit angiogenesis
[56]. A recent study showed that pRB-E2F complexes repress endo-
thelial cell vascular endothelial growth factor receptor transcription
[57]. Moreover, RB-deficient tumors that have increased vascularity
[58–61] exhibited significantly reduced NOL7 protein expression
(Figure 7). We have previously demonstrated that reexpressing NOL7
in CC cells that have reduced pRB and NOL7 expression inhibited
tumor angiogenesis [6]. This suggests that there may be a connection
between RB loss–mediated reduction in NOL7 expression and in-
creased vascularity observed in RB-deficient tumors. Our data suggest
that RB-mediated activation of NOL7 transcription may be crucial for
maintaining cells in a relatively anti-angiogenic state through steady
NOL7 expression. Subsequently, inactivation of RB in human malig-
nancies negatively regulates NOL7 expression, thereby shifting the
tumor microenvironment to a more pro-angiogenic state that stimu-
lates tumor growth and progression (Figure 8).
In conclusion, this study has further characterized the transcriptional
activator function of pRB. Our data also provide evidence to support
the hypothesis that reactivation of pRB may influence multiple anti-
angiogenic pathways through its regulation of NOL7. Several natural
and synthetic compounds have demonstrated their anti-angiogenic
activity by increasing levels of hypophosphorylated and active pRB
[56,62]. This knowledge may be exploited in the future to design
Figure 8. Model illustrating the mechanism by which pRB inhibits angiogenesis through transcriptional activation of NOL7.
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more comprehensive anti-angiogenic therapies that target multiple
angiogenic pathways, thereby promising longer term efficacy.
Acknowledgments
We thank Kay Macleod for her valuable input and help in setting up
this study.
References
[1] Folkman J (1990). What is the evidence that tumors are angiogenesis dependent?
J Natl Cancer Inst 82, 4–6.
[2] Folkman J and Hanahan D (1991). Switch to the angiogenic phenotype during
tumorigenesis. Princess Takamatsu Symp 22, 339–347.
[3] Grépin R and Pagès G (2010). Molecular mechanisms of resistance to tumour
anti-angiogenic strategies. J Oncol 2010, 835680.
[4] Weis SM and Cheresh DA (2011). Tumor angiogenesis: molecular pathways
and therapeutic targets. Nat Med 17, 1359–1370.
[5] Bergers G and Hanahan D (2008). Modes of resistance to anti-angiogenic therapy.
Nat Rev Cancer 8, 592–603.
[6] Hasina R, Pontier AL, FeketeMJ, Martin LE, Qi XM, Brigaudeau C, Pramanik R,
Cline EI, Coignet LJ, and Lingen MW (2006). NOL7 is a nucleolar candidate
tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype.
Oncogene 25, 588–598.
[7] Doçi CL, Zhou G, and Lingen MW (in revision). The novel tumor suppressor
NOL7 post-transcriptionally regulates thrombospondin-1 expression. Oncogene.
[8] Doçi CL, Mankame TP, Langerman A, Ostler KR, Kanteti R, Best T, Onel K,
Godley LA, Salgia R, and Lingen MW (2012). Characterization of NOL7 gene
point mutations, promoter methylation, and protein expression in cervical cancer.
Int J Gynecol Pathol 31, 15–24.
[9] Huang L, Zheng M, Zhou Q-M, Zhang M-Y, Yu Y-H, Yun J-P, and Wang
H-Y (2012). Identification of a 7-gene signature that predicts relapse and sur-
vival for early stage patients with cervical carcinoma.Med Oncol 29, 2911–2918.
[10] Rader JS, Gerhard DS, O’Sullivan MJ, Li Y, Li L, Liapis H, and Huettner PC
(1998). Cervical intraepithelial neoplasia III shows frequent allelic loss in 3p and
6p. Genes Chromosomes Cancer 22, 57–65.
[11] Zhang Z, Borecki I, Nguyen L,MaD, Smith K,Huettner PC,MutchDG,Herzog
TJ, Gibb RK, Powell MA, et al. (2007). CD83 gene polymorphisms increase
susceptibility to human invasive cervical cancer. Cancer Res 67, 11202–11208.
[12] Mankame TP, Zhou G, and Lingen MW (2010). Identification and character-
ization of the human NOL7 gene promoter. Gene 456, 36–44.
[13] Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, and Tommasino M (2009).
The biological properties of E6 and E7 oncoproteins from human papilloma-
viruses. Virus Genes 40, 1–13.
[14] Chen W, Li F, Mead L, White H, Walker J, Ingram DA, and Roman A (2007).
Human papillomavirus causes an angiogenic switch in keratinocytes which is
sufficient to alter endothelial cell behavior. Virology 367, 168–174.
[15] Burkhart DL and Sage J (2008). Cellular mechanisms of tumour suppression by
the retinoblastoma gene. Nat Rev Cancer 8, 671–682.
[16] Moody CA and Laimins LA (2010). Human papillomavirus oncoproteins:
pathways to transformation. Nat Rev Cancer 10, 550–560.
[17] Nam EJ, Kim JW, Kim SW, Kim YT, Kim JH, Yoon BS, Cho NH, and Kim S
(2007). The expressions of the Rb pathway in cervical intraepithelial neoplasia;
predictive and prognostic significance. Gynecol Oncol 104, 207–211.
[18] Johung K, Goodwin EC, and DiMaio D (2007). Human papillomavirus E7
repression in cervical carcinoma cells initiates a transcriptional cascade driven
by the retinoblastoma family, resulting in senescence. J Virol 81, 2102–2116.
[19] Decesse JT, Medjkane S, Datto MB, and Cremisi CE (2001). RB regulates
transcription of the p21/WAF1/CIP1 gene. Oncogene 20, 962–971.
[20] Ianari A, Natale T, Calo E, Ferretti E, Alesse E, Screpanti I, Haigis K, Gulino A,
and Lees JA (2009). Proapoptotic function of the retinoblastoma tumor sup-
pressor protein. Cancer Cell 15, 184–194.
[21] Howley P, Scheffner M, Huibregtse J, and Münger K (1991). Oncoproteins
encoded by the cancer-associated human papillomaviruses target the products
of the retinoblastoma and p53 tumor suppressor genes. Cold Spring Harb Symp
Quant Biol 56, 149–155.
[22] Liu X, Roberts J, Dakic A, Zhang Y, and Schlegel R (2008). HPV E7 contributes
to the telomerase activity of immortalized and tumorigenic cells and augments
E6-induced hTERT promoter function. Virology 375, 611–623.
[23] Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, Sabatini
DM, Chen IS, Hahn WC, Sharp PA, et al. (2003). Lentivirus-delivered stable
gene silencing by RNAi in primary cells. RNA 9, 493–501.
[24] Dirlam A, Spike BT, and Macleod KF (2007). Deregulated E2f-2 underlies cell
cycle and maturation defects in retinoblastoma null erythroblasts. Mol Cell Biol
27, 8713–8728.
[25] Flowers S, Beck GR, and Moran E (2010). Transcriptional activation by pRB
and its coordination with SWI/SNF recruitment. Cancer Res 70, 8282–8287.
[26] Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, Van Lint C, Aunis D,
and Rohr O (2007). Recruitment of chromatin-modifying enzymes by CTIP2
promotes HIV-1 transcriptional silencing. EMBO J 26, 412–423.
[27] Vieira KF, Levings PP, Hill MA, Crusselle VJ, Kang SH, Engel JD, and Bungert
J (2004). Recruitment of transcription complexes to the β-globin gene locus
in vivo and in vitro. J Biol Chem 279, 50350–50357.
[28] Deng W-G, Zhu Y, Montero A, and Wu KK (2003). Quantitative analysis
of binding of transcription factor complex to biotinylated DNA probe by a
streptavidin-agarose pulldown assay. Anal Biochem 323, 12–18.
[29] Wu KK (2006). Analysis of protein-DNA binding by streptavidin-agarose pull-
down. Methods Mol Biol 338, 281–290.
[30] Darnell GA, Schroder WA, Antalis TM, Lambley E, Major L, Gardner J, Birrell
G, Cid-Arregui A, and Suhrbier A (2007). Human papillomavirus E7 requires
the protease calpain to degrade the retinoblastoma protein. J Biol Chem 282,
37492–37500.
[31] Lehman TA, Modali R, Boukamp P, Stanek J, Bennett WP, Welsh JA, Metcalf
RA, Stampfer MR, Fusenig N, Rogan EM, et al. (1993). p53 Mutations in
human immortalized epithelial cell lines. Carcinogenesis 14, 833–839.
[32] Macleod KF, Hu Y, and Jacks T (1996). Loss of Rb activates both p53-dependent
and independent cell death pathways in the developing mouse nervous system.
EMBO J 15, 6178–6188.
[33] Phelps WC, Yee CL, Munger K, and Howley PM (1988). The human papilloma-
virus type 16 E7 gene encodes transactivation and transformation functions similar
to those of adenovirus E1A. Cell 53, 539–547.
[34] Thomas M, Kalita A, Labrecque S, Pim D, Banks L, and Matlashewski G
(1999). Two polymorphic variants of wild-type p53 differ biochemically and
biologically. Mol Cell Biol 19, 1092–1100.
[35] Murai Y, Hayashi S, Takahashi H, Tsuneyama K, and Takano Y (2005). Cor-
relation between DNA alterations and p53 and p16 protein expression in cancer
cell lines. Pathol Res Pract 201, 109–115.
[36] Morris EJ and Dyson NJ (2001). Retinoblastoma protein partners. Adv Cancer
Res 82, 1–54.
[37] Trimarchi JM and Lees JA (2002). Sibling rivalry in the E2F family. Nat Rev
Mol Cell Biol 3, 11–20.
[38] Werner T (2000). Computer-assisted analysis of transcription control regions.
Matinspector and other programs. Methods Mol Biol 132, 337–349.
[39] Farre D, Roset R, Huerta M, Adsuara JE, Rosello L, Alba MM, and Messeguer
X (2003). Identification of patterns in biological sequences at the ALGGEN
server: PROMO and MALGEN. Nucl Acids Res 31, 3651–3653.
[40] Chen P-L, Scully P, Shew J-Y, Wang JYJ, and Lee W-H (1989). Phosphoryla-
tion of the retinoblastoma gene product is modulated during the cell cycle and
cellular differentiation. Cell 58, 1193–1198.
[41] Burke JR, Deshong AJ, Pelton JG, and Rubin SM (2010). Phosphorylation-
induced conformational changes in the retinoblastoma protein inhibit E2F trans-
activation domain binding. J Biol Chem 285, 16286–16293.
[42] Lundberg AS and Weinberg RA (1998). Functional inactivation of the retino-
blastoma protein requires sequential modification by at least two distinct cyclin-
cdk complexes. Mol Cell Biol 18, 753–761.
[43] Knudsen ES and Wang JY (1997). Dual mechanisms for the inhibition of E2F
binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol
Cell Biol 17, 5771–5783.
[44] Connell-Crowley L, Harper JW, and Goodrich DW (1997). Cyclin D1/Cdk4
regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phos-
phorylation. Mol Biol Cell 8, 287–301.
[45] Lees JA, Buchkovich KJ, Marshak DR, Anderson CW, and Harlow E (1991).
The retinoblastoma protein is phosphorylated on multiple sites by human cdc2.
EMBO J 10, 4279–4290.
[46] Lee EY, Cam H, Ziebold U, Rayman JB, Lees JA, and Dynlacht BD
(2002). E2F4 loss suppresses tumorigenesis in Rb mutant mice. Cancer Cell 2,
463–472.
[47] Fiedler M, Müller-Holzner E, Viertler H-P, Widschwendter A, Laich A, Pfister G,
Spoden GA, Jansen-Dürr P, and Zwerschke W (2004). High level HPV-16 E7
Neoplasia Vol. 14, No. 12, 2012 pRB Transcriptionally Activates NOL7 Expression Mankame and Lingen 1221
oncoprotein expression correlates with reduced pRb-levels in cervical biopsies.
FASEB J 18, 1120–1122.
[48] Wiest T, Schwarz E, Enders C, Flechtenmacher C, and Bosch FX (2002).
Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers
with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 21,
1510–1517.
[49] Yuan J, Knorr J, Altmannsberger M, Goeckenjan G, Ahr A, Scharl A, and
Strebhardt K (1999). Expression of p16 and lack of pRB in primary small cell
lung cancer. J Pathol 189, 358–362.
[50] Damjanovich J, Adány R, Berta A, Beck Z, and Balázs M (2000). Mutation
of the RB1 gene caused unilateral retinoblastoma in early age. Cancer Genet
Cytogenet 119, 1–7.
[51] Cook KM and Figg WD (2010). Angiogenesis inhibitors: current strategies and
future prospects. CA Cancer J Clin 60, 222–243.
[52] Chen H-Z, Tsai S-Y, and Leone G (2009). Emerging roles of E2Fs in cancer:
an exit from cell cycle control. Nat Rev Cancer 9, 785–797.
[53] Nowling T, Bernadt C, Johnson L, Desler M, and Rizzino A (2003). The
co-activator p300 associates physically with and can mediate the action of the
distal enhancer of the FGF-4 gene. J Biol Chem 278, 13696–13705.
[54] Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, and Zhao K (2009).
Genome-wide mapping of HATs and HDACs reveals distinct functions in
active and inactive genes. Cell 138, 1019–1031.
[55] Visel A, Blow MJ, Li Z, Zhang T, Akiyama JA, Holt A, Plajzer-Frick I,
Shoukry M, Wright C, Chen F, et al. (2009). ChIP-seq accurately predicts tissue-
specific activity of enhancers. Nature 457, 854–858.
[56] Gabellini C, Del Bufalo D, and Zupi G (2006). Involvement of RB gene family
in tumor angiogenesis. Oncogene 25, 5326–5332.
[57] Pillai S, KovacsM, andChellappan S (2010). Regulation of vascular endothelial growth
factor receptors by Rb and E2F1: role of acetylation. Cancer Res 70, 4931–4940.
[58] Rossler J, Dietrich T, Pavlakovic H, Schweigerer L, Havers W, Schuler A, Bornfeld
N, and Schilling H (2004). Higher vessel densities in retinoblastoma with local
invasive growth and metastasis. Am J Pathol 164, 391–394.
[59] Zaghloul MS, El Naggar M, El Deeb A, Khaled H, and Mokhtar N (2000).
Prognostic implication of apoptosis and angiogenesis in cervical uteri cancer.
Int J Radiat Oncol Biol Phys 48, 1409–1415.
[60] Lucchi M, Mussi A, Fontanini G, Faviana P, Ribechini A, and Angeletti CA
(2002). Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur
J Cardiothorac Surg 21, 1105–1110.
[61] Mikulić D, Ilić I, Cepulić M, Orlić D, Giljević JS, Fattorini I, and Seiwerth S
(2004). Tumor angiogenesis and outcome in osteosarcoma. Pediatr Hematol
Oncol 21, 611–619.
[62] Stengel KR, Thangavel C, Solomon DA, Angus SP, Zheng Y, and Knudsen ES
(2009). Retinoblastoma/p107/p130 pocket proteins: protein dynamics and inter-
actions with target gene promoters. J Biol Chem 284, 19265–19271.
1222 pRB Transcriptionally Activates NOL7 Expression Mankame and Lingen Neoplasia Vol. 14, No. 12, 2012
Table W1. Luciferase Assay Primers.













Table W2. SAPA and DNAse I Footprinting Assay Primers.
Construct/DNA Primer Sequence 5′-3′ Modification
NOL7 FL Forward CACGGCGGCCATCTGCTA 5′ Biotin
Reverse CTGACCTCTGACCCGGAAGCA
R1 Forward CACGGCGGCCATCTGCTA 5′ Biotin
Reverse ACGGCTCACGCTGTCCGGTGCTC
R2 Forward CAGCCCTGTCTCGCCATCCC 5′ Biotin
Reverse GTGGGCGTGTTTCTTTCCACGT
R3 Forward TGCCTACAGGCCACGCCCTTC 5′ Biotin
Reverse CTGACCTCTGACCCGGAAGCA
p21 Forward GGAAATTGCAGAGAGGTGCATCG 5′ Biotin
Reverse TCGGCAGCTGCTCACACCTC
R02 Forward CCAAATGAAGCTGAGCTTGGTGCT 5′ Biotin
Reverse AACAGAGTCAAAAACTGCAAGGCTGCC
NOL7 FL FAM Forward CACGGCGGCCATCTGCTA 5′ 6-FAM
Reverse CTGACCTCTGACCCGGAAGCA
Figure W1. NOL7 expression is downregulated in G2/M cell cycle phases, which have phosphorylated pRB. (A) Schematic for cell cycle
arrest treatment. Briefly, cells were cultured in media containing aphidicolin (2 ng/ml) or nocodazole (40 ng/ml; Sigma) for the indicated
times to arrest them in G1 and G2 phases, respectively. Following incubation, media without drug were added to cells for the indicated
times to release them in early S andM phases, respectively. Finally, cells were harvested and lysed, and proteins were analyzed byWestern
blot analysis as described before. (B)Western blot analysis was used to assess pRB, ppRB, NOL7, and actin levels in cells arrested at various
cell cycle phases.
Figure W2. pRB, pRB-interacting TFs, and RNA Pol II are enriched
on the NOL7 promoter. Biotinylated NOL7, p21 promoters, and non-
genic region R02 were incubated with HaCaT nuclear extract and
precipitated with streptavidin beads, and the coprecipitated proteins
were analyzed by Western blot analysis.
